Purpose. There are, in general, few published series on chordoma. It is a rare disease and further data are still needed. Patients The data of 37 patients with chordoma were retrospectively analyzed. Treatment was surgical excision in 11, radical radiotherapy in 9 and a combination of the two in 16 cases. The male to female ratio was 2.7"1. Median age was 59 years (range 1-89 years).
Introduction
Chordomas are rare turnouts that arise along the axial skeleton with the sacro-coccygeal and the spheno-occipital regions being the two most favoured sites. 1'2 They are generally considered to arise from remnants of notochordal tissue. 3 Surgery and radiation therapy are the main lines of treatment. However, the close proximity of these turnouts to critical neural and skeletal tissues can compromise both the radical approach of surgical resection and radiation dose. Radiotherapy is usually recommended in inoperable cases, following surgery, or for the treatment of gross recurrence. 4 The timing of radiotherapy and the optimum radiation dose and fractionation have not been established. Local control is poor and death is most often caused by consequences of uncontrolled local tumour growth. 6 Distant metastases are not uncommon but their frequency varies widely between published series. 1'7 No chemotherapeutic regimen has been shown to be effective against these tumours. 4 '8 In general, there are few published series on chordoma, and because of the rarity of the disease few publications contain more than 25 patients. No prospective randomized studies have been reported.
Hence, in most cases, the available data in the literature represent selected patients. This may explain partially the discrepancies between results, and more clinical reports are therefore still needed. This paper represents the first published description of the Danish experience in the management of patients with chordoma.
Patients and methods
This national Danish study of 37 patients represents all the patients treated in the three major sarcoma centres in Denmark in the last 25 years. The files of all patients were reviewed and all histopathological 
Results

Natural history
In Denmark, between one and five chordomas are diagnosed per year. In the present series, there were 27 males and 10 females, i.e. the male to female ratio was 2.7"1. The age of patients ranged from 1 to 89 years with a median age of 59 years. Median duration of symptoms before admission was 12 months (range 1-84 months). Symptoms dominating at diagnosis were pain (98%), neurological disturbances (42%) and incontinence (33%).
The tumours were located in the sacro-coccygeal region in 25 patients (68%), spheno-occipital region in six patients (16%) and vertebrae in six patients (16%). The median value of 'maximum tumour diameter' was estimated to be 7 cm (range 1-30 cm), with the large tumours mainly seen at the sacral region; however, it should be noted that the methods used to measure turnout size varied from simple clinical judgement to measurements based on magnetic resonance scanning.
Treatment results
Of the 27 patients in whom an attempt at surgical excision was part of their initial treatment, a wide safety margin could be achieved in only four cases (all sacral). Surgery was intra-lesional in 17 cases and marginal in six cases. After the initial primary surgery, only the four patients with wide safety margins were evaluated as being in complete remission.
Radiotherapy was given with conventional fractionation (1. The actuarial 5-year rates of overall, progressionfree and symptom-free survival (_ 1 SE) were 40% (___9%), 31% (_8%) and 20% (___7%), respect- ively. The corresponding 10-year rates were 26% (+__8%),21% (___7%) and 14% (_6%) for overall, progression-free and symptom-free survival, respectively (Fig. 1) .
Prognostic f acwrs
As seen in Table 1 , the outcome of therapy (5-year overall, progression-free and symptom-free survival) did not differ between the various treatment groups. Table 2 shows that with the exception of tumour site, none of the prognostic factors studied was found to affect survival, progression-free survival or symptom-free survival. Continuous variables (age, tumour size and radiation dose) were divided into two at the median values. To compensate for the variation in fractionation schedules the total dose was calculated in terms of biological effective dose (BED) using the equation:
where n number of fractions, d dose per fraction and ,/ for chordoma was estimated to be 7 Gy. Still, no effect of BED was found on survival, progression-free survival and symptom-free survival.
Patients with chordomas of the spheno-occipital region did much worse than patients with chordomas in any other site. None of the patients with spheno-occipital tumours survived for 5 years. This difference in survival was statistically significant (p 0.001), while there was no difference in survival between vertebral and sacral chordomas (Fig. 2) . Until recently, sex was not thought to be of prognostic value in chordomas.'60'Connell et al., 4 however, suggested that female sex was an independent predictor of shortened survival in base of skull chordomas. The same observation was reported by 15 Thieblemont et al., in a study of 26 cases of chordomas in various sites. They defined a favourable group of males younger than 60 years, and an unfavourable group of females and males older than 60 years. We were unable to reproduce this observation in our study. Given the small number of patients in their study, the prognostic value of combined gender and age reported by Thieblemont et al. still has to be confirmed by other studies. Although not generally accepted, some studies have reported a trend for patients over 40 years of age to have a worse prognosis, 4 especially with base of skull chordomas. 16 In the present study, age did not have an effect on survival.
O'Connell et al. have found that patients with base of skull chordomas larger than 70 ml have a significantly worse survival than those with smaller tumours.
14 Although intuitively obvious, the study 4 was Pathological features such as ploidy were reported to show a statistical trend for prognostic significance in chordoma patients. 3 Also, chondroid chordoma subtype is known to carry a better prognosis. 16 None of the cases reported here was described as chondroid chordoma. The metastasis rate of 23% reported here confirms the potential metastatic nature of chordomas stated in most of the recent literature.
1, [4] [5] [6] The factors that can affect radiation response such as total dose, radiation quality and technique varied significantly in this small cohort of patients. This may explain the absence of any correlation between the radiation parameters and any of the studied endpoints. To compensate for the variation in fractionation schedules the total dose was calculated in terms of BED. The It is important to emphasize that even after a long survival time, late recurrences can occur and few of the patients alive would be without active disease.
More disturbing is the fact that even fewer patients are actually symptom free.
None of our patients with spheno-occipital chordomas survived for 5 years. This could be explained in part by the absence of chondroid chondromas in this series, the favourable histological subtype in this material. These poor survival results illustrate the limited ability of conventional treatments for chordomas of the base of the skull. A recent study using charged heavy particle beam radiotherapy reported a 5-year local control rate of 580/0. 19 We conclude that effective treatments for chordomas are still lacking. Although a group of patients may be long-term survivors, very few are symptomfree and in general the prognosis is rather poor. A multi-institutional prospective registration study may provide more information on the optimal workup and treatment of this rare disease.
